Thomas Jonassen
Förmögenhet: 5 M $ per 2026-05-31
Förmögenhet: 5 M $ per 2026-05-31
Thomas Jonassen is the founder.
Dr. Jonassen was the founder of Action Pharma A, founded in 2000, holding the title of Chief Scientific Officer.
Dr. Jonassen is also the founder of TXP Pharma GmbH,ResoTher Pharma AS.
Dr. Jonassen is currently an Associate Professor at the University of Copenhagen and the Chief Scientific Officer at SynAct Pharma AB starting in 2024.
Dr. Jonassen holds a doctorate from the University of Copenhagen.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
SYNACT PHARMA AB 4,77 % | 2025-12-19 | 2 545 320 ( 4,77 % ) | 5 M $ | 2026-05-31 |
| Företag | Position | Start |
|---|---|---|
| SYNACT PHARMA AB | Teknisk/Vetenskaplig/F&U Direktör | - |
University of Copenhagen
University of Copenhagen Other Consumer ServicesConsumer Services Functions as a College/University | Företagsledare/Principal | - |
ResoTher Pharma AS
ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops peptide-based drugs | Grundare | - |
| Företag | Position | Slut |
|---|---|---|
TXP Pharma GmbH | Grundare | - |
Action Pharma A/S
Action Pharma A/S BiotechnologyHealth Technology Manufactures biopharmaceutical products | Grundare | - |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 5 |
|---|---|
University of Copenhagen
University of Copenhagen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Action Pharma A/S
Action Pharma A/S BiotechnologyHealth Technology Manufactures biopharmaceutical products | Health Technology |
SynAct Pharma AB
SynAct Pharma AB Pharmaceuticals: MajorHealth Technology Provides pharmaceutical drugs for treatment inflammatory diseases | Health Technology |
TXP Pharma GmbH | |
ResoTher Pharma AS
ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops peptide-based drugs | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån